FY2025 EPS Estimates for Certara Reduced by Leerink Partnrs

Certara, Inc. (NASDAQ:CERT - Free Report) - Analysts at Leerink Partnrs decreased their FY2025 earnings per share estimates for shares of Certara in a research report issued on Tuesday, July 8th. Leerink Partnrs analyst M. Cherny now anticipates that the company will post earnings per share of $0.28 for the year, down from their previous forecast of $0.29. The consensus estimate for Certara's current full-year earnings is $0.28 per share. Leerink Partnrs also issued estimates for Certara's FY2028 earnings at $0.44 EPS.

CERT has been the subject of a number of other reports. Robert W. Baird increased their price target on Certara from $9.00 to $13.00 and gave the company a "neutral" rating in a research note on Friday, April 11th. KeyCorp decreased their price target on Certara from $18.00 to $15.00 and set an "overweight" rating for the company in a research note on Monday. Morgan Stanley began coverage on Certara in a research note on Thursday, July 3rd. They set an "equal weight" rating and a $16.00 price target for the company. Barclays raised Certara from an "equal weight" rating to an "overweight" rating and raised their price objective for the stock from $11.00 to $14.00 in a research note on Thursday, May 8th. Finally, JMP Securities reissued a "market perform" rating on shares of Certara in a research note on Tuesday, May 6th. Four analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $15.29.

Certara Price Performance

NASDAQ CERT traded up $0.05 on Friday, reaching $11.14. 3,241,814 shares of the stock traded hands, compared to its average volume of 1,755,752. The firm's fifty day simple moving average is $11.42 and its 200 day simple moving average is $11.88. The company has a quick ratio of 2.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.27. The company has a market cap of $1.81 billion, a price-to-earnings ratio of -557.00 and a beta of 1.43. Certara has a 12 month low of $8.64 and a 12 month high of $16.93.

Certara (NASDAQ:CERT - Get Free Report) last posted its earnings results on Monday, May 5th. The company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.10 by $0.04. Certara had a positive return on equity of 5.05% and a negative net margin of 0.67%. The firm had revenue of $106.00 million for the quarter, compared to analysts' expectations of $104.44 million. During the same period last year, the firm earned $0.10 EPS. The firm's revenue was up 9.7% compared to the same quarter last year.

Institutional Trading of Certara

A number of hedge funds have recently modified their holdings of the business. AdvisorNet Financial Inc purchased a new stake in shares of Certara in the second quarter valued at $25,000. Harbor Capital Advisors Inc. lifted its holdings in shares of Certara by 41.3% in the second quarter. Harbor Capital Advisors Inc. now owns 28,670 shares of the company's stock valued at $335,000 after purchasing an additional 8,376 shares in the last quarter. Jane Street Group LLC lifted its holdings in shares of Certara by 17.1% in the first quarter. Jane Street Group LLC now owns 277,054 shares of the company's stock valued at $2,743,000 after purchasing an additional 40,463 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Certara by 13.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 299,528 shares of the company's stock valued at $2,965,000 after purchasing an additional 35,954 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its holdings in shares of Certara by 65.6% during the first quarter. Goldman Sachs Group Inc. now owns 228,996 shares of the company's stock worth $2,267,000 after acquiring an additional 90,724 shares in the last quarter. Hedge funds and other institutional investors own 73.96% of the company's stock.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.